Considering that over-activation of NRF2 is more frequent in squamous cell than non-squamous cell lung cancers, and NRF2 is involved in resistance to chemotherapy and kinase targeted therapy [27, 28], this difference may account for superior efficacy of nedaplatin against squamous cell lung cancer. Here, NFE2L2 is linked to squamous cell lung carcinoma.